The T cell immune response against SARS-CoV-2
P Moss - Nature immunology, 2022 - nature.com
The adaptive immune response is a major determinant of the clinical outcome after SARS-
CoV-2 infection and underpins vaccine efficacy. T cell responses develop early and …
CoV-2 infection and underpins vaccine efficacy. T cell responses develop early and …
[HTML][HTML] Characteristics of SARS-CoV-2 and COVID-19
B Hu, H Guo, P Zhou, ZL Shi - Nature reviews microbiology, 2021 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute …
and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute …
Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19
ATTACC, ACTIV-4a, and REMAP-CAP … - New England Journal …, 2021 - Mass Medical Soc
Background Thrombosis and inflammation may contribute to the risk of death and
complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized …
complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis
Importance Effective therapies for patients with coronavirus disease 2019 (COVID-19) are
needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced …
needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced …
Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report
Remap-Cap Investigators, AC Gordon, PR Mouncey… - MedRxiv, 2021 - medrxiv.org
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
Genetic mechanisms of critical illness in COVID-19
Host-mediated lung inflammation is present, and drives mortality, in the critical illness
caused by coronavirus disease 2019 (COVID-19). Host genetic variants associated with …
caused by coronavirus disease 2019 (COVID-19). Host genetic variants associated with …
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients …
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients …
Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results
WHO Solidarity Trial Consortium - New England journal of …, 2021 - Mass Medical Soc
Abstract Background World Health Organization expert groups recommended mortality trials
of four repurposed antiviral drugs—remdesivir, hydroxychloroquine, lopinavir, and interferon …
of four repurposed antiviral drugs—remdesivir, hydroxychloroquine, lopinavir, and interferon …